Microbix' board members have extensive experience
that is relevant and helpful to the company. Their
qualifications include accounting and finance, contracts and law, life sciences and medical care, as well as corporate governance.
The board takes an active role in developing vision and strategy, advising management on key matters and providing oversight on policies and reporting.
Mr. Gastle is the founder of Microbix and has served as a Director since its inception. He is the Chairman of the Board. Mr. Gastle is primarily responsible for setting the strategic direction of the Company and is the principal architect of the Company’s business development activities.
Dr. Cochran has been serving on the board since 1988. His professional experience spans all levels of the drug discovery and development value chain including operational and executive roles in venture capital, pharmaceutical and biotechnology industries. His previous experience includes Bayer Pharmaceuticals, last serving as Vice President of Business Development, Biotechnology, in Berkeley, California. He is currently Managing Director, Johns Hopkins HealthCare Solutions, an operating division of Johns Hopkins Medicine/ HealthCare.
Mr. Groome is the President and CEO of Microbix. Before joining Microbix, he was CEO of Avivagen. He also has experience as E.V.P. Corporate and Strategic Development at Bioniche Life Sciences and headed the life sciences investment banking activities for a major national investment dealer. He has more than 20 years of experience as an equity analyst, industry commentator, investment banker, and corporate advisor in the life sciences industry. He also serves as a member of the life sciences Advisory Board of the Department of Foreign Affairs and international Trade of the Government of Canada and as a Director of ScarX Therapeutics.
Mr. Embro-Pantalony has served as a Director of the Company since 2007. He has held several executive positions in life sciences with responsibility for licensing, business development, and strategic planning, including VP Finance & CFO of Novopharm Limited; VP, Information Technology & CIO of Bayer Inc., VP, Finance & Administration of Bayer Healthcare; and General Manager, Nitrogen Products for Terra International (Canada) Ltd. He is a Chartered Director (C. Dir.) and Audit Committee Certified (A.C.C.) through the Directors College, McMaster University.
Dr. Blecher is the founder of several start-up biotechnology ventures, the last of which, Sequent Biotechnologies, Inc., was purchased by Microbix in 2005. He practices Emergency Medicine at Lakeridge Health Hospital, and chronic pain medicine at CPM Centres for Pain Management, the largest network of pain management clinics in Canada, currently with nine clinics, where he is Medical Director of Interventional Training.
Mr. Marino has over 30 years of experience in corporate legal roles and executive management functions, with particular emphasis in transaction based activities related to domestic and international corporate development. He also has considerable experience in conflict resolution and litigation management.
Mr. Renner, CEO and partner in Zydus Pharmaceuticals, Pennington N.J., has over 25 years experience in the pharmaceutical industry. He has had a successful career leading businesses with many drug approvals in the US.